Among these six proteomic markers, namely, complement factor B, serotransferrin, catalase, proteasome subunit beta type-6, beta-2-microglobulin, and protocadherin-18, they were reported to have high diagnostic potential for endometrial cancer, and suprabasin was identified as a potential marker for poor-prognostic endometrial cancer [28,57]. This evidence concerns the gene B2M and endometrial cancer.